Press Releases Equillium, Inc.

Equities

EQ

US29446K1060

Real-time Estimate Cboe BZX Other stock markets 01:36:48 2024-06-10 pm EDT			5-day change	1st Jan Change
0.713 ^USD	-10.99%		-51.03%	-0.43%

Jun. 04	Equillium, Inc. Announces Topline Data from Its Phase 2, Single Dose, Proof-Of-Concept Study of Eq101	CI
May. 14	Equillium, Inc. Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Equillium Reports Inducement Grant under Nasdaq Listing Rule 5635(4)	Jun. 06	AQ
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Jun. 05	BU
Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata	Jun. 04	BU
Equillium to Present at the Jefferies Global Healthcare Conference	May. 29	BU
Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease	May. 14	BU
Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights	May. 09	BU
Equillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists	May. 07	BU
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Apr. 03	BU
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis	Apr. 01	BU
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights	Mar. 25	BU
Equillium to Present at the H.C. Wainwright Autoimmune and Inflammatory Disease Conference and the LD Micro Invitational Conference	Mar. 25	AQ
Equillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational Conference	Mar. 22	BU
EQUILLIUM : 2024 INDUCEMENT PLAN - Form 8-K	Mar. 08	PU
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 and EQ102 in Development for Alopecia Areata and Celiac Disease	Dec. 22	AQ
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease	Dec. 21	BU
EQ Bank Card launches in Québec as Carte Banque EQ	Nov. 20	AQ
Equillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of Rheumatology	Nov. 13	BU
Equillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates	Nov. 08	BU
Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology	Nov. 06	BU
Equillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of Rheumatology	23-10-19	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Equillium, Inc.

Equities

EQ

US29446K1060

Press Releases

Filters